ABBV vs REGN
By Alex · Tickerpine
AbbVie Inc. vs Regeneron Pharmaceuticals, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | REGN |
|---|---|---|
| Price | $295.03 | $955.47 |
| Market cap | $521.50B | $98.84B |
| P/E ratio | 50.7 | 21.1 |
| ROE | — | 14.95% |
| Profit margin | 15.67% | 28.51% |
| Revenue growth | 10.30% | 36.30% |
| Dividend yield | 2.35% | 0.39% |
| Beta | 0.19 | 0.10 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs REGN in plain English
- ABBV is the bigger company — about 5.3× the market cap of REGN.
- REGN is cheaper on earnings (P/E 21.1 vs 50.7).
- REGN is growing revenue faster (36% vs 10%).
- ABBV has the higher dividend yield (2.35% vs 0.39%).
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
REGN return calculator
See what $1,000 in Regeneron Pharmaceuticals, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.